Monte Rosa Therapeutics is seeking a highly motivated and innovative synthetic chemist to contribute to the advancement of our molecular glue degrader (MGD) platform. This role is ideally suited to a scientist with deep expertise in synthetic organic chemistry and a strong track record in developing novel methodologies to access differentiated chemical space.
Working within a highly collaborative and interdisciplinary environment, you will play a key role in designing and expanding proprietary small-molecule libraries to support the discovery of transformative therapies. The position calls for scientific creativity, technical excellence, and the ability to bridge cutting-edge synthetic chemistry with modern medicinal chemistry principles.
• Design and develop innovative small-molecule libraries targeting previously undruggable proteins using MGD approaches• Act as a key driver in the evolution of the chemistry platform through the development of novel synthetic methodologies and reaction design• Plan and oversee synthesis strategies executed through a global CRO network• Integrate biological data (ADME, pharmacology) to inform compound design and optimization• Collaborate closely with multidisciplinary teams (chemistry, biology, computational sciences) to ensure timely delivery of project milestones• Strengthen technical capabilities to enhance innovation and efficiency• Document and communicate scientific findings through internal reports, patents, and peer-reviewed publications
• PhD in Synthetic Organic Chemistry; postdoctoral experience in academia or industry is preferred• Strong expertise in complex molecule synthesis and/or reaction and methodology development• Demonstrated track record of scientific impact through publications and/or patents• Solid understanding of medicinal chemistry principles and their application in drug discovery• Experience in parallel synthesis would be advantageous• Experience with CRO collaborations is advantageous but not essential, including exposure to outsourced synthesis strategies• Sound understanding of preclinical drug discovery, including ADME and developability considerations• Familiarity with chemical databases, visualization tools, and molecular modelling (e.g. Maestro)• Awareness of emerging discovery modalities (e.g. DEL, direct-to-biology approaches)• Excellent interpersonal and communication skills, with the ability to foster effective scientific collaboration• Proactive, forward-thinking mindset with a strong interest in innovation and continuous development
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.
